美国 · 平台与数据 · Benzinga
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

详细摘要
Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies cleared Klygefa for…
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.benzinga.com)



